US companies disagree over what the mutual recognition agreement with the EU might mean for them
This article was originally published in Clinica
Not all US medical technology companies are enthusiastic about the pending mutual recognition agreement between the US and the European Union. Karen Riley reports from the Health Industry Manufacturers Association annual meeting last week in Rancho Mirage, California.
You may also be interested in...
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.